TrialThe New England journal of medicine2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Hussein A Tawbi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1,181 papers cite itlatest 60 shown
this paperpooled ittrialcites it